Lung Cancer

Nov 29, 2024

Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of the total lung cancers in the United States. Almost 500K cases in the 7MM were diagnosed in 2022 alone. Moreover, significant deaths were recorded at the end of the same year. Analysis indicates that the most common ge...

Nov 29, 2024

Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of all lung cancers. the total number of incident cases of NSCLC across the 7MM was approximately 500,000 in 2022 and is projected to reach around 600,000 cases by 2032. Studies show that non-small cell lung cancer aff...

Nov 29, 2024

Lung cancer, to date, remains the leading cause of death worldwide, however, the epidemiological analysis depicts varying NSCLC incidence all over the world. In 2022, there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths. The number of people living for at least five years after ...

Sep 20, 2024

NSCLC is the most common type of lung cancer accounting for approximately 85% of all lung cancers (roughly 509,000 incident cases in 2019 [7MM: the US, EU4 and the UK, and Japan]). The real-world treatment trend depicts a significant shift towards targeted and immunotherapies (from only systemic therapies in the pa...

Oct 17, 2023

South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain On October 12, 2023, South Rampart Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track status to its drug candidate, SRP-001, intended for the management of acute pain. SRP-001 is a...

Sep 08, 2023

Lung cancer remains the leading cause of cancer-related death in the United States. The American Cancer Society estimates 238,340 people will be diagnosed with lung cancer in 2023, with non-small cell lung cancer (NSCLC) accounting for the majority of cases (roughly 80% to 85%).The treatment paradigm of antibody-dr...

Sep 05, 2023

FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations (BTDs) in the United States for the treatment of adult patients with unresectable or metastati...

May 23, 2023

FDA Approves RINVOQ as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease AbbVie announced that the FDA had approved RINVOQ® (upadacitinib) for treating people with moderately to highly active Crohn's disease who have had an unsatisfactory response or intolerance to one or more TNF blockers. Thi...

Mar 23, 2023

Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal Aortic Aneurysm On March 21, 2023, Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced it had received U.S. Food and Drug Administration (FDA) 510(k) clearance for its algorithm intended to ...

Nov 29, 2022

C4X Discovery Holdings and AstraZeneca Signs Exclusive USD 402 Million Global License C4X Discovery Holdings has signed an exclusive global license with AstraZeneca worth up to USD 402 million for the development and commercialization of the NRF2 Activator program. The agreement will allow AstraZeneca to develop...